Olema is a preclinical biopharmaceutical organization creating innovative medications for the management and prevention of estrogen receptor (ER) positive breast cancer. At Olema, we harness the intricate understanding of the molecular mechanism of the ER to formulate compounds that surpass both the existing medications and those under development.